Mymd Pharmaceuticals (NASDAQ:QCLS) Announces Earnings Results

Mymd Pharmaceuticals (NASDAQ:QCLS – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.14) earnings per share for the quarter, FiscalAI reports.

Mymd Pharmaceuticals Price Performance

QCLS opened at $0.32 on Tuesday. The firm’s fifty day simple moving average is $0.68. Mymd Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $8.17.

Analyst Ratings Changes

Several research firms have recently issued reports on QCLS. Wall Street Zen upgraded shares of Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, September 19th. Weiss Ratings raised shares of Mymd Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Mymd Pharmaceuticals has a consensus rating of “Sell”.

View Our Latest Research Report on QCLS

About Mymd Pharmaceuticals

(Get Free Report)

MyMD Pharmaceuticals is a clinical-stage biopharmaceutical company that has focused on developing treatments for inflammatory and age-related conditions. Its work has centered on drug candidates intended to address diseases for which existing treatment options may be limited. The company’s lead candidate, MYMD-1, is an investigational oral therapy designed to regulate inflammatory processes and the immune system. MyMD has studied its potential application across a range of chronic conditions; it is not an approved medicine.

Featured Stories

Receive News & Ratings for Mymd Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mymd Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.